. . "RIV/00064203:_____/12:8515!RIV13-MZ0-00064203" . . "0862-8947" . "Inkretinov\u00E1 terapie vykazuje velmi dobrou klinickou \u00FA\u010Dinnost a bezpe\u010Dnost. Pozitivn\u00ED ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDch rizikov\u00FDch faktor\u016F je v souladu s v\u00FDsledky prvn\u00EDch metaanal\u00FDz ji\u017E proveden\u00FDch klinick\u00FDch studi\u00ED, kter\u00E9 prokazuj\u00ED v\u00FDznamn\u00E9 sn\u00ED\u017Een\u00ED kardiovaskul\u00E1rn\u00EDho rizika." . "CZ - \u010Cesk\u00E1 republika" . "Inkretinov\u00E1 terapie: ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika" . . "Kvapil, Milan" . "22" . . "1"^^ . "2" . "6"^^ . . "http://www.remedia.cz/Okruhy-temat/Kardiologie/8-18.folder.aspx" . "I" . "Incretin therapy; cardiovascular risk reduction"@en . . "Incretin therapy has very good clinical efficacy and safety. A positive effect on cardiovascular risk factors is consistent with the results of the first meta-analyzes already conducted clinical studies that have shown a significant reduction in cardiovascular risk."@en . . "1"^^ . . "Incretin therapy: cardiovascular risk reduction"@en . . "Incretin therapy: cardiovascular risk reduction"@en . . "Inkretinov\u00E1 terapie: ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika"@cs . "Inkretinov\u00E1 terapie: ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika" . . "141897" . "Inkretinov\u00E1 terapie vykazuje velmi dobrou klinickou \u00FA\u010Dinnost a bezpe\u010Dnost. Pozitivn\u00ED ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDch rizikov\u00FDch faktor\u016F je v souladu s v\u00FDsledky prvn\u00EDch metaanal\u00FDz ji\u017E proveden\u00FDch klinick\u00FDch studi\u00ED, kter\u00E9 prokazuj\u00ED v\u00FDznamn\u00E9 sn\u00ED\u017Een\u00ED kardiovaskul\u00E1rn\u00EDho rizika."@cs . "[34580377EC18]" . "Inkretinov\u00E1 terapie: ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika"@cs . "RIV/00064203:_____/12:8515" . . "Remedia" . .